SAGE Therapeutics (SAGE) Rating Increased to Sell at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of SAGE Therapeutics (NASDAQ:SAGE) from a strong sell rating to a sell rating in a report released on Monday morning.

Several other brokerages have also weighed in on SAGE. ValuEngine lowered SAGE Therapeutics from a strong-buy rating to a buy rating in a research report on Wednesday, January 2nd. Morgan Stanley cut their price target on SAGE Therapeutics from $230.00 to $213.00 and set an overweight rating on the stock in a research report on Wednesday, December 19th. Wolfe Research assumed coverage on SAGE Therapeutics in a research report on Friday, December 14th. They set an outperform rating on the stock. LADENBURG THALM/SH SH set a $210.00 price target on SAGE Therapeutics and gave the stock a buy rating in a research report on Tuesday, December 11th. Finally, Oppenheimer set a $170.00 price target on SAGE Therapeutics and gave the stock a buy rating in a research report on Tuesday, November 20th. Two equities research analysts have rated the stock with a sell rating and thirteen have given a buy rating to the company. The company currently has an average rating of Buy and an average target price of $200.58.

NASDAQ SAGE traded down $2.57 during trading hours on Monday, reaching $123.65. The stock had a trading volume of 15,897 shares, compared to its average volume of 775,087. SAGE Therapeutics has a 52-week low of $79.88 and a 52-week high of $195.97. The firm has a market cap of $5.62 billion, a P/E ratio of -17.56 and a beta of 2.62.

SAGE Therapeutics (NASDAQ:SAGE) last issued its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($2.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.41) by ($0.22). During the same period last year, the business earned ($1.97) earnings per share. As a group, sell-side analysts anticipate that SAGE Therapeutics will post -7.75 earnings per share for the current year.

Several large investors have recently modified their holdings of the company. Vanguard Group Inc increased its stake in SAGE Therapeutics by 6.9% during the third quarter. Vanguard Group Inc now owns 4,085,812 shares of the biopharmaceutical company’s stock worth $577,121,000 after acquiring an additional 262,990 shares during the last quarter. Vanguard Group Inc. raised its position in shares of SAGE Therapeutics by 6.9% during the 3rd quarter. Vanguard Group Inc. now owns 4,085,812 shares of the biopharmaceutical company’s stock worth $577,121,000 after purchasing an additional 262,990 shares during the period. Kepos Capital LP acquired a new stake in shares of SAGE Therapeutics during the 3rd quarter worth approximately $1,254,000. Mackenzie Financial Corp increased its position in SAGE Therapeutics by 9.5% in the 3rd quarter. Mackenzie Financial Corp now owns 17,175 shares of the biopharmaceutical company’s stock valued at $2,426,000 after acquiring an additional 1,486 shares during the period. Finally, Point72 Asset Management L.P. increased its position in SAGE Therapeutics by 25.0% in the 3rd quarter. Point72 Asset Management L.P. now owns 175,000 shares of the biopharmaceutical company’s stock valued at $24,719,000 after acquiring an additional 35,000 shares during the period.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Further Reading: Technical Analysis of Stocks and What It Means

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply